Cargando…

1976. Pooled Analysis of Safety Data From Phases 2 and 3 Clinical Trials Evaluating Eravacycline in Complicated Intra-Abdominal Infections

BACKGROUND: Eravacycline is a novel, fully synthetic fluorocycline antibiotic that was evaluated in three comparator-controlled studies for the treatment of complicated intra-abdominal infections (cIAI). The objective of this analysis was to evaluate the safety profile of eravacycline 1 mg/kg IV q12...

Descripción completa

Detalles Bibliográficos
Autores principales:	Efimova, Ekaterina, Olesky, Melanie, Izmailyan, Sergey, Tsai, Larry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253170/ http://dx.doi.org/10.1093/ofid/ofy210.1632

Ejemplares similares

1978. Efficacy of Eravacycline in Secondary Bacteremia: A Post Hoc Analysis of Two Phase 3 studies of Complicated Intra-Abdominal Infection
por: Lawrence, Kenneth, et al.
Publicado: (2018)

1963. Combined Microbiological Response Rates From Two Phase 3 Trials Demonstrating the Activity of Eravacycline in the Treatment of Complicated Intra-abdominal Infections: A Pooled Analysis of IGNITE1 and IGNITE4
por: Newman, Joseph, et al.
Publicado: (2018)

2264. An Evaluation of Empiric Treatment Patterns for Adult Patients with Community-Onset (CO) “Low-Risk” (LR) Complicated Intra-Abdominal Infections (cIAI) Across US Hospitals
por: Lodise, Thomas, et al.
Publicado: (2019)

Pharmacokinetics (PK) of Eravacycline in Subjects with Renal or Hepatic Impairment Compared with Healthy Subjects
por: Horn, Patrick, et al.
Publicado: (2017)

Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eravacycline
por: Newman, Joseph V., et al.
Publicado: (2018)

An Evaluation of Treatment Patterns and Associated Outcomes Among Adult Hospitalized Patients With Lower-Risk Community-Acquired Complicated Intra-abdominal Infections: How Often Are Expert Guidelines Followed?
por: Lodise, Thomas P, et al.
Publicado: (2020)

Mass Balance and Drug Interaction Potential of Intravenous Eravacycline Administered to Healthy Subjects
por: Newman, Joseph V., et al.
Publicado: (2019)

Eravacycline: A Review in Complicated Intra-Abdominal Infections
por: Scott, Lesley J.
Publicado: (2019)

Correction to: Eravacycline: A Review in Complicated Intra-Abdominal Infections
por: Scott, Lesley J.
Publicado: (2019)

Efficacy and Safety of Eravacycline in Obese Patients: A Post Hoc Analysis of Pooled Data From the IGNITE1 and IGNITE4 Clinical Trials
por: Asempa, Tomefa E, et al.
Publicado: (2020)

915. Global 2018 Surveillance of Eravacycline Against Gram-positive Pathogens, Including Resistant Isolates
por: Morgan, Steven, et al.
Publicado: (2020)

2259. Predictors of Empiric Carbapenem Therapy in Complicated Intra-Abdominal Infections in the United States, 2013–2017: A Retrospective Cohort Study
por: Zilberberg, Marya, et al.
Publicado: (2019)

The Efficacy and Safety of Eravacycline in the Treatment of Complicated Intra-Abdominal Infections: A Systemic Review and Meta-Analysis of Randomized Controlled Trials
por: Lan, Shao-Huan, et al.
Publicado: (2019)

1613. Global 2018 Surveillance of Eravacycline Against Gram-negative Pathogens, Including Multi-drug Resistant Isolates
por: Lijfrock, Virgil, et al.
Publicado: (2020)

633. Eravacycline Use in Immunocompromised Patients: Multicenter Evaluation of Clinical and Safety Endpoints
por: Kunz Coyne, Ashlan J, et al.
Publicado: (2022)

The efficacy and safety of eravacycline compared with current clinically common antibiotics in the treatment of adults with complicated intra-abdominal infections: A Bayesian network meta-analysis
por: Meng, Rui, et al.
Publicado: (2022)

In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017
por: Morrissey, Ian, et al.
Publicado: (2020)

1243. Eravacycline in Bacteremia: A Case Series
por: Andrade, Justin A, et al.
Publicado: (2021)

In Vitro Activity of Eravacycline against Gram-Positive Bacteria Isolated in Clinical Laboratories Worldwide from 2013 to 2017
por: Morrissey, Ian, et al.
Publicado: (2020)

1430. Eravacycline associated hypofibrinogenemia during treatment of M.abscessus
por: Rausch, Ethan, et al.
Publicado: (2022)

IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections
por: Solomkin, Joseph S, et al.
Publicado: (2019)

Carbapenem Treatment and Outcomes Among Patients With Culture-Positive Complicated Intra-abdominal Infections in US Hospitals: A Retrospective Cohort Study
por: Zilberberg, Marya D, et al.
Publicado: (2019)

1577. Real-World, Multicenter Experience with Eravacycline for Various Infections
por: Alosaimy, Sara, et al.
Publicado: (2020)

In Vitro Activity of Eravacycline and Comparator Antimicrobials Against 143 Strains of Bacteroides Species.
por: Citron, Diane, et al.
Publicado: (2017)

390. Eravacycline combination therapy for severe, recurrent, or fulminant Clostridioides difficile infection
por: Morrison, Austin R, et al.
Publicado: (2022)

560. Repurposing Eravacycline for the Treatment of SARS-CoV-2 Infections
por: Reig, Núria, et al.
Publicado: (2020)

2137. Real World Experience with Eravacycline for the Treatment of Infections Caused by Carbapenem-Resistant Acinetobacter baumannii
por: Lim, Andy, et al.
Publicado: (2023)

1270. Early Real-world Evidence in the Use of Eravacycline for the Management of Draconian Infections
por: Carr, Amy, et al.
Publicado: (2020)

1259. Activity of eravacycline against staphylococci isolated from periprosthetic joint infections
por: Zhuchenko, Georg, et al.
Publicado: (2020)

644. Comparative Evaluation of ETEST® ERV bioMérieux with the CLSI Broth Microdilution Method for Eravacycline MIC Determination
por: Sauvonnet, Veronique, et al.
Publicado: (2019)

728. Activity of Eravacycline Against Contemporary Gram-Negative Clinical Isolates From New York City Hospitals
por: Iregui, Alejandro, et al.
Publicado: (2019)

710. In Vitro Activity and Performance of Available Susceptibility Testing Methods for Eravacycline Against Carbapenem-Resistant Enterobacteriaceae (CRE)
por: Jones, Chelsea E, et al.
Publicado: (2019)

1154. Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-abdominal Infection: A Phase 2, Randomized Clinical Trial
por: Jackson, Carl-Christian A, et al.
Publicado: (2021)

2132. Multicenter Evaluation of Eravacycline MIC Results for Enterobacteriaceae Using MicroScan Dried Gram-Negative MIC Panels
por: Traczewski, Maria M, et al.
Publicado: (2019)

The role of the intra-abdominal view in complicated intra-abdominal infections
por: Tolonen, Matti, et al.
Publicado: (2019)

253 Activity of Eravacycline Against Enterobacteriaceae and Acinetobacter baumannii from New York City
por: Abdallah, Marie, et al.
Publicado: (2014)

Intra-Abdominal Effusions of Traumatic Origin
Publicado: (1919)

2106. Desirability of Outcome Ranking (DOOR): Application to a Phase 3 Registrational Trial Evaluating Sulopenem for Patients with Complicated Intra-abdominal Infection (cIAI)
por: Aronin, Steven I, et al.
Publicado: (2023)

A Real-World Assessment of Clinical Outcomes and Safety of Eravacycline: A Novel Fluorocycline
por: Van Hise, Nicholas, et al.
Publicado: (2020)

688. In Vitro Activity of Eravacycline, a New Tetracycline Analog, and Comparators Against the Six Most Commonly Isolated Ribotypes of Clostridioides difficile
por: Basseres, Eugenie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_n1phvq02h97nb64etuthtrnfo7